4.6 Article

Validity Evidence for the Research Category, Cognitively Unimpaired - Declining, as a Risk Marker for Mild Cognitive Impairment and Alzheimer's Disease

期刊

FRONTIERS IN AGING NEUROSCIENCE
卷 13, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2021.688478

关键词

cognitively unimpaired; subclinical decline; transitional cognitive decline; mild cognitive impairment; Alzheimer's disease; validity; biomarkers

资金

  1. National Institutes of Health [RF-1 AG027161, R01 AG021155, P30 AG062715, P50 AG033514, S10 OD025245-01]
  2. Alzheimer's Association [AARF-19-614533, R01A6062167, R01AG070940]
  3. AA-FAIM [R01 AG54059]

向作者/读者索取更多资源

This study found that subtle cognitive decline occurs years before a clinical diagnosis of mild cognitive impairment or dementia due to Alzheimer's disease is made. Operational criteria can detect subclinical decline that may signal Alzheimer's disease or other dementia risk.
While clinically significant cognitive impairment is the key feature of the symptomatic stages of the Alzheimer's disease (AD) continuum, subtle cognitive decline is now known to occur years before a clinical diagnosis of mild cognitive impairment (MCI) or dementia due to AD is made. The primary aim of this study was to examine criterion validity evidence for an operational definition of cognitively unimpaired-declining (CU-D) in the Wisconsin Registry for Alzheimer's Prevention (WRAP), a longitudinal cohort study following cognition and risk factors from mid-life and on. Cognitive status was determined for each visit using a consensus review process that incorporated internal norms and published norms; a multi-disciplinary panel reviewed cases first to determine whether MCI or dementia was present, and subsequently whether CU-D was present, The CU-D group differed from CU-stable (CU-S) and MCI on concurrent measures of cognition, demonstrating concurrent validity. Participants who changed from CU-S to CU-D at the next study visit demonstrated greater declines than those who stayed CU-S. In addition, those who were CU-D were more likely to progress to MCI or dementia than those who were CU-S (predictive validity). In a subsample with positron emission tomography (PET) imaging, the CU-D group also differed from the CU-S and MCI/Dementia groups on measures of amyloid and tau burden, indicating that biomarker evidence of AD was elevated in those showing sub-clinical (CU-D) decline. Together, the results corroborate other studies showing that cognitive decline begins long before a dementia diagnosis and indicate that operational criteria can detect subclinical decline that may signal AD or other dementia risk.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据